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OBJECTIVE — The increased cardiovascular risk in diabetes has been linked to endothelial
and renal dysfunction. The aim of this study was to investigate the role of stable fragments of the
precursors of adrenomedullin, endothelin-1, vasopressin, and atrial natriuretic peptide in pro-
gression of cardiovascular disease in patients with diabetes.
RESEARCH DESIGN AND METHODS — This was a prospective, observational study
design with a composite end point (death or unexpected admission to hospital due to a cardio-
vascular event) on 781 patients with type 2 diabetes (54 events, median duration of observation
15 months). The four stable precursor peptides midregional adrenomedullin (MR-proADM),
midregional proatrial natriuretic peptide (MR-proANP), COOH-terminal proendothelin-1 (CT-
proET-1), and COOH-terminal provasopressin or copeptin (CT-proAVP) were determined at
baseline, and their association to renal function and cardiovascular events was studied using
stepwiselinearandCoxlogisticregressionanalysisandreceiveroperatingcharacteristicanalysis,
respectively.
RESULTS — MR-proADM, CT-proET-1, CT-proAVP, and MR-proANP were all elevated in
patients with future cardiovascular events and independently correlated to serum creatinine.
MR-proADM and MR-proANP were signiﬁcant predictors of a future cardiovascular event, with
MR-proANP being the stronger (area under the curve 0.802  0.034, sensitivity 0.833, speci-
ﬁcity 0.576, positive predictive value 0.132, and negative predictive value 0.978 with a cutoff
value of 75 pmol/l).
CONCLUSIONS — The four serum markers of vasoactive and natriuretic peptides are re-
lated to both kidney function and cardiovascular events, thus linking two major complications
of diabetes, diabetic nephropathy and cardiovascular disease.
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T
he main cause of death in patients
with diabetes is cardiovascular dis-
ease: two of three diabetic patients
develop heart failure or die from myocar-
dial infarction or stroke, and diabetes is
an established independent cardiovascu-
lar risk factor (1). There is clear evidence
that hyperglycemia and hyperinsulin-
emia, both of which occur in type 2 di-
abetes, are linked to endothelial
dysfunction resulting in atherosclerosis
and, eventually, cardiovascular disease
(2). On the other hand, in patients with
diabetes, other risk factors such as hyper-
tension,dyslipidemia,andcentralobesity
are frequently present as well, clustered
together in the metabolic syndrome. Sev-
eral risk scores that take into account the
above-mentioned factors have been de-
veloped to estimate cardiovascular risk in
diabetes, and additional prognostic pa-
rameters including C-reactive protein and
otherinﬂammatoryfactorscanhelpidentify
thosewithanexcessiveriskforeventsinthe
future (2).
One risk factor for cardiovascular
events is diabetic nephropathy. The pres-
ence of nephropathy is a marker for en-
dothelial damage, but neurohumoral
factors are thought to contribute to the
additional risk (3).
There are several vasoactive peptides
with both cardiovascular and renal ef-
fects;amongthemarethenatriureticpep-
tides atrial natriuretic peptide and brain
natriuretic peptide, vasopressin, and the
mainlyendothelium-derivedpeptidesad-
renomedullin and endothelin-1, which
also act as both vasoactive and natriuretic
agents.
The main problem in measuring
plasma concentrations of these peptides
in a clinical setting is their rapid degrada-
tion and binding to receptors or binding
proteins: ANP, for example, has a plasma
half-life of 2–3 min. Therefore, assays
have been developed to detect cleavage
products of the preproproteins (4–7).
These peptides are released in equimo-
lar concentrations and serve as stable
surrogate parameters for their active
counterparts.
Recently, the following stable plasma
markers of vasoactive peptides have been
shown to predict outcome after myocar-
dial infarction or in chronic heart fail-
ure: midregional adrenomedullin (MR-
proADM) (8), COOH-terminal
provasopressin or copeptin (CT-proAVP)
(9,10), COOH-terminal proendothelin-1
(CT-proET-1) (11), and midregional
proatrial natriuretic peptide (MR-proANP)
(10, 12–14).
It has been shown in patients with
type 2 diabetes that MR-proADM is asso-
ciated with vascular function parameters
and increased in those with elevated se-
rum creatinine (15) and that it correlates
to BMI in morbid obesity (16). Although
CT-proET-1 has not been studied in the
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been shown to be upregulated in diabetes
(17)andtolimitinsulinaction(18).Only
little is known about the role of the two
otherpeptidesindiabetes:AVPisupregu-
lated in the hypothalamus of diabetic rats
(19), and ANP has been proposed to be
involved in the hyperﬁltration in hyper-
glycemia, contributing to the develop-
ment of diabetic nephropathy (20). The
aim of the current study was to study the
relationship of the four plasma parame-
ters with renal function and with future
cardiovascular events in a prospective
manner in a population of type 2 diabetic
patients.
RESEARCH DESIGN AND
METHODS— A total of 781 consecu-
tive diabetic patients, mean  SEM age
59  0.5 years and diabetes duration
11.8  0.4 years, treated at the diabetes
outpatient clinic of the University Clinics
of Vienna from 1 January 2006 to 17 Feb-
ruary 2007 were studied. Upon entry in
the study, a careful medical history with
special focus on cardiovascular disease
was taken, and history of ischemic heart
disease (IHD) was recorded. All patients
were asked to complete the Minnesota
Living with Heart Failure questionnaire
and the Dyspnoe score chart. Blood pres-
sure, heart rate, electrocardiogram, and a
blood sample for the determination of se-
rum cholesterol, triglycerides, creatinine,
A1C, blood glucose, and the markers
were obtained from each patient, and
New York Heart Association (NYHA)
stage was assessed.
The study was conducted in accor-
dance with the Declaration of Helsinki II
andwasapprovedbythelocalethicscom-
mittee. All participants gave written in-
formed consent.
Laboratory procedures
Total cholesterol, LDL cholesterol, HDL
cholesterol, triglycerides, blood glucose,
A1C, and serum creatinine were deter-
mined using standard laboratory proce-
dures. Glomerular ﬁltration rate (GFR)
was calculated by the Cockroft-Gault and
Modiﬁcation of Diet in Renal Disease for-
mulas, respectively. CT-proAVP, CT-
proET-1, MR-proADM, and MR-proANP
weredeterminedfromEDTAplasmaofall
patients at baseline with sandwich immu-
noluminometric assays (all from
B.R.A.H.M.S., Hennigsdorf, Berlin, Ger-
many), as described before (4–7).
End points
Based on the short observation period, a
composite end point consisting of un-
planned hospitalization for cardiovascu-
lar disease or death was chosen as the
primary end point in this study. Un-
planned cardiovascular events were de-
ﬁned as follows: hospitalization based on
heartfailure,myocardialinfarctionorun-
stable angina, symptomatic bradycardia,
atrial ﬁbrillation, ventricular tachycardia,
peripheral and central arterial occlusive
disease, transient ischemic attack, or
stroke. All patients were traced through
thenationalregistryduring2007.Mortal-
ity data were obtained from the Austrian
Central Ofﬁce of Civil Registration (Zen-
trales Melderegister). If a patient had
died, the date of death was recorded. Re-
portsabouthospitalizationwereobtained
from the regional hospital data network
(Krankenanstaltenverbund). Information
about hospitalizations for cardiovascular
disease was obtained from hospital ﬁles
byacardiologist,unawareoftheresultsat
index time.
Statistical analysis
VariablesareexpressedasmeansSEMor
mean [95% CI], as stated. Sample size cal-
culation was based on an expected log haz-
ard ratio (HR) of 0.5 and an expected event
rate of 10%. For 0.05 and power
90%, a sample size of 600 patients was
obtained.
Forgroupcomparisonsofcontinuous
variables, a two-tailed Student’s t test was
used. Categorical variables were evalu-
ated with a 
2 test. Associations of vari-
ables with NYHA stage were tested using
Spearman’s rank test.
Receiver operating characteristic
analysis was performed to evaluate the
predictive performance of MR-proADM,
CT-proET-1, MR-proANP, and CT-
proAVP. A forced-entry model was used
to evaluate the role of creatinine and the
four peptide markers MR-proADM, CT-
proET-1, MR-proANP, and CT-proAVP
as independent predictors of reaching the
endpoint(unplannedhospitalizationdue
to cardiovascular event and/or death).
Variables, NYHA stage, IHD history,
age, BMI, systolic blood pressure, A1C,
LDL cholesterol, serum triglycerides, and
serum creatinine were included in the
models, with or without the addition of
either one of the four peptide markers.
Again, HRs are given as 1-SD increment.
The results were retested in a stepwise
Cox regression model.
Stepwise logistic regression models
were calculated to identify independent
variables to predict the reaching of the
endpoint(unplannedhospitalizationdue
to cardiovascular event and/or death).
The P value for entering the stepwise
model was set at 0.05 and for exclusion
was set to 0.10. The stepwise approach
was used to determine the most potent
predictors independent of the number of
events out of the variables as follows:
NYHA stage, IHD history, age, BMI, sys-
tolic blood pressure, A1C, LDL choles-
terol, serum triglycerides, serum
creatinine, MR-proADM, CT-proET-1,
MR-proANP, and CT-proAVP. All results
of the regression model are presented us-
ing HRs Exp(B). HRs are given per 1-SD
increment. In addition, 500 bootstrap
repetitions were done for the Cox regres-
sion model, repeating the variable selec-
tion for each sample using the same
entering and exclusion rules. This boot-
strapping procedure is used as a test
against overﬁtting the Cox regression
model. We counted how often a variable
was entered into the Cox regression mod-
els.Theresultswereretestedinaforcedin
model.
Theproportionalhazardsassumption
was assessed and satisﬁed for all variables
based on time interaction test. To deter-
mine independent predictors of serum
creatinine, stepwise linear regression was
performed. Parameters included in the
model were age (years), total and LDL
cholesterol (milligrams per deciliter),
A1C (percent), systolic and diastolic
blood pressure RR (millimeters of mer-
cury), heart rate (minute
1), BMI (weight
in kilograms divided by the square of
heightinmeters),CT-proAVP(picomoles
per liter), CT-proET-1 (picomoles per li-
ter), MR-proADM (nanomoles per liter),
and MR-proANP (picomoles per liter).
P  0.05 was considered statistically
signiﬁcant. Statistical software SPSS for
Windows (release 15.0; SPSS, Chicago,
IL) was used for analysis.
RESULTS
Metabolic characterization and
outcome
Anoverviewofthedemographicandmet-
abolic parameters of the study group is
given in Table 1. Of the entire study pop-
ulation54patientsreachedthecomposite
end point during the observation period
of up to 22 months (15  6.9 months,
median  SD). They were signiﬁcantly
different from their event-free counter-
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creatinine (P  0.002), NYHA classiﬁca-
tion (P  0.0001), but not A1C, total and
LDL cholesterol, systolic and diastolic
blood pressure, and Dyspnoe score.
Plasma markers
In contrast with A1C, glucose and serum
lipids, MR-proADM (0.93  0.07 vs.
0.62  0.01 nmol/l, P  0.0001), MR-
proANP (220.0  25.6 vs. 86.8  2.6
pmol/l,P0.0001),CT-proET(197.6
7.0 vs. 72.6  0.9 pmol/l, P  0.001),
andCT-proAVP(16.01.8vs.9.50.5
pmol/l, P  0.001) were all signiﬁcantly
higher in patients reaching the composite
endpointthaninthosewhodidnot.With
increasing NYHA stage, the serum levels
of the four peptides also increased signif-
icantly(Ptrend0.001forallcorrelations,
as assessed by Spearman’s rank test).
In addition, age, serum triglycerides,
A1C, systolic RR, serum creatinine, and
GFR (calculated by both Cockroft-Gault
and Modiﬁcation of Diet in Renal Disease
formulas) were signiﬁcantly associated
with NYHA stage (P  0.001). In con-
trast, there was no signiﬁcant correlation
with serum cholesterol, LDL cholesterol,
diastolic blood pressure, plasma glucose,
or BMI.
Plasma markers and cardiovascular
events and death
Receiver operating characteristic analysis
wasusedtoevaluatetheabilityofthefour
marker peptides MR-proADM, CT-
proET-1, MR-proANP, and CT-proAVP
to predict the primary end point. Areas
under the curve (AUCs) of these models
were 0.802  0.034 (MR-proANP),
0.698  0.04 (MR-proADM), 0.690 
0.038 (CT-proAVP), and 0.652  0.048
(CT-proET) (P  0.001 for all four mark-
ers). Using a cutoff value of 75 pmol/l,
MR-proANP in this sample showed a sen-
sitivity of 0.833, a speciﬁcity of 0.576, a
positive predictive value (PPV) of 0.132,
and a negative predictive value (NPV) of
0.978. The corresponding values for the
three other markers are as follows: MR-
proADM (cutoff 0.5 pmol/l): sensitivity
0.796, speciﬁcity 0.395, PPV 0.099, and
NPV0.960;CT-proAVP(cutoff5pmol/l):
sensitivity 0.833, speciﬁcity 0.406, PPV
0.099, and NPV 0.972; and CT-proET
(cutoff 60 pg/ml): sensitivity 0.722, spec-
iﬁcity 0.325, PPV 0.078, and NPV 0.942.
Logistic Cox regression forced-entry
analysis was used to identify independent
predictors of reaching the composite end
point. Creatinine was an independent
predictor of cardiovascular events but be-
cameinsigniﬁcantuponadditionofanyof
the four markers. MR-proADM and MR-
proANPbutnotCT-proETorCT-proAVP
were signiﬁcant predictors of an event
(Table 2) (for a direct comparison of the
ﬁve models, see supplementary Tables
A1–A5, available in an online appendix
at http://care.diabetesjournals.org/cgi/
content/full/dc08-2168/DC1). In step-
wise Cox regression models all four
hormones remained signiﬁcant markers
of outcome (data not shown).
When stepwise regression analysis
was performed including all four hor-
monesbesideallriskparameters(asmen-
tioned in STATISTICAL ANALYSIS), only MR-
proANP, together with NYHA stage and
IHD history, remained a signiﬁcant pre-
dictorofcardiovasculareventoccurrence;
a 1-SD increment of MR-proANP was as-
sociated with a 1.564-fold risk (95% CI
1.360–1.798, P  0.000) (supplemen-
tary Table A6, available in an online ap-
pendix). This result also held true if a
forced-entry model was calculated (data
not shown).
Bootstrap testing supported the im-
portance and robustness of the model
(supplementary Table A7). Of the
bootstrap samples, 97.4% included
MR-proANP.
Relation of plasma markers to renal
parameters
Signiﬁcant correlations were seen be-
tweenserumcreatinine(orGFR,ascalcu-
lated by the Cockroft-Gault or MDRD
formulas, respectively) and the plasma
markers, as determined by linear regres-
sion analysis (R
2: MR-proADM 0.401,
MR-proANP0.341,CT-proET0.319,and
C-proAVP 0.443, P  0.001 for all pa-
rameters). The plasma markers also cor-
related signiﬁcantly with each other (not
shown). In a stepwise linear regression
analysis (Table 3), in which all hormones
besides classic risk factors were included,
all four plasma markers remained inde-
pendent predictors of serum creatinine.
CONCLUSIONS — There are three
main ﬁndings in this study. 1) In diabetic
patients, progression to cardiovascular
eventsisassociatedwiththeplasmalevelsof
MR-proADM, CT-proAVP, CT-proET-1,
and MR-proANP; 2) MR-proANP and MR-
proADM are signiﬁcant independent
predictors of cardiovascular events in
this patient group; and 3) all four mark-
ers are independent from each other
predictor of serum levels of creatinine
(and of GFR).
Plasma levels of all four markers were
signiﬁcantly higher in patients reaching
the composite end point and signiﬁcantly
higherinpatientswithincreasingseverity
of cardiac symptoms at baseline as as-
sessed by NYHA stage. All four markers
were useful as predictors of future cardio-
vascular events, with MR-proANP being
the strongest. In this sample, the two
markers MR-proADM and MR-proANP
proved to be stronger predictors of an
event than traditional risk markers. CT-
pro-AVP and CT-proET only remained
signiﬁcant in a stepwise but not in a
forced-entry Cox regression model. Of
note, all four parameters showed a very
good negative predictive quality, a prop-
erty that would be very valuable were
these parameters to be used in a clinical
Table 1—Baseline characteristics of the study population
Baseline
Age (years) 59.05  0.5
Sex distribution (male/female) (%) 65.1/43.9
A1C (%) 7.82  0.06
History of cardiovascular disease (%) 17.2
NYHA class distribution (I/II/III/IV) (%) 71.6/20.9/7.2/0.4
Serum creatinine (mg/dl) 1.05  0.02
GFR (ml/min per 1.73 m
2) 91.17  1.37
Serum cholesterol (mg/dl) 197.5  1.8
LDL cholesterol (mg/dl) 110.3  1.3
Systolic blood pressure RR (mmHg) 141.7  0.8
Diastolic blood pressure RR (mmHg) 83.9  0.5
MR-proANP (pmol/l) 96.63  1.02
MR-proADM (nmol/l) 0.64  0.01
CT-proET (pmol/l) 74.63  1.02
CT-proAVP (pmol/l) 9.88  0.43
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currently has a lower risk for the occur-
rence of a cardiovascular event over the
nextyearhelpsclinicianstobettertargetag-
gressive management and close monitoring
to those who really have a higher risk.
NH2-terminal-pro brain natriuretic
peptide, another natriuretic peptide
marker,alsoshowedahighNPVinapop-
ulation comparable to the sample pre-
sented here. Again, NT-poBNP was
superior to traditional risk factors in the
prediction of cardiovascular events (21).
MR-proANP, the strongest predictor in
this sample, has been studied in compar-
ison with NT-proBNP as the survival pre-
dictor in the setting of chronic heart
failure (12) and acute cardiac failure and
has been found to be noninferior to this
established parameter.
It has been shown repeatedly that di-
abetic nephropathy is a main risk factor
for future cardiovascular events (22). In
conﬁrmationoftheseobservations,inthis
sample serum creatinine was signiﬁcantly
higher and glomerular ﬁltration rate was
signiﬁcantly lower in those reaching the
composite end point over the short time
frame of a little more than 1 year. In ad-
dition, baseline serum creatinine was
strongly associated with all four serum
markers of vascular function, and all four
remained independent predictors of se-
rum creatinine in the stepwise linear re-
gression model. Although creatinine was
a highly signiﬁcant predictor of outcome
in a model including traditional risk
markers,itbecameinsigniﬁcantifanyone
of the four markers were added. Both ad-
renomedullin and endothelin may be
produced by renal endothelial cells and
have been studied in the context of ne-
phropathy and renal failure (23); in this
sample of diabetic patients the stable se-
rum markers MR-proADM and CT-
proET-1 also correlated with GFR and
serum creatinine. In another sample of
type 2 diabetic patients MR-proADM was
increased in the presence of nephropathy
and was related to insulin resistance (15).
The markers MR-proANP and CT-
proAVP have been studied in the context
of sepsis and myocardial infarction (24)
and have been used as outcome parame-
ters regarding morbidity and mortality.
These parameters, to our knowledge,
have not been studied in patients with
diabetes and in the context of diabetic
nephropathy. However, CT-proAVP
(copeptin) has been shown to correlate
negatively with GFR in chronic heart fail-
ure (10), and MR-proANP was negatively
correlated with serum creatinine in
chronic heart failure (13). Thus, the close
relationship of these parameters both
with MR-proADM and CT-proET as well
as with serum creatinine is noteworthy. It
is not known how the precursor peptides
of the vasoactive peptides are cleared
Table 3—Association of variables with serum creatinine using stepwise linear regression
analysis
Standardized
coefﬁcient TP
CT-proAVP (pmol/l) 0.443 13.335 0.0001
MR-proADM (pmol/l) 0.177 4.005 0.0001
MR-proANP (pmol/l) 0.163 4.102 0.0001
CT-proET (pg/ml) 0.166 4.457 0.0001
Heart rate (min
1) 0.092 3.390 0.001
Systolic blood pressure RR (mmHg) 0.054 1.987 0.047
AdjustedR
2ofthemodelwas0.61l.Variablesnotincludedinthemodelwereage,totalandLDLcholesterol,
triglycerides, A1C, fasting glucose, BMI, and diastolic RR.
Table 2—Comparison of association of known risk factors and the four markers with cardiovascular events
NYHA Age Creatinine
Model 1
Signiﬁcance 0.004 0.000 0.042
Wald 8.275 13.025 4.116
Exp(B) (95% CI) 1.689 (1.182–2.413) 1.833 (1.319–2.547) 1.125 (1.004–1.260)
Model 2 CT-proAVP
Signiﬁcance 0.004 0.000 NS NS
Wald 8.253 12.434 — —
Exp(B) (95% CI) 1.687 (1.181–2.411) 1.819 (1.304–2.537) — —
Model 3 CT-proET
Signiﬁcance 0.022 0.001 NS NS
Wald 5.208 11.187 — —
Exp(B) (95% CI) 1.546 (1.063–2.247) 1.752 (1.261–2.434) — —
Model 4 MR-proADM
Signiﬁcance 0.028 0.004 NS 0.018
Wald 4.810 8.278 — 5.553
Exp(B) (95% CI) 1.526 (1.046–2.226) 1.658 (1.175–2.341) — 1.346 (1.051–1.724)
Model 5 MR-proANP
Signiﬁcance NS NS NS 0.000
Wald — — — 31.191
Exp(B) (95% CI) — — — 1.850 (1.491–2.297)
Logistic regression models using the following parameters (forced entry): NYHA, age, serum creatinine, LDL cholesterol, serum triglycerides, A1C, systolic RR, BMI
(model 1) and the same parameters plus CT-proAVP (model 2), CT-proET (model 3), MR-proADM (model 4), or MR-proANP (model 5), respectively. Only
parameters reaching signiﬁcance are shown (see supplementary material for the full models). Exp(B) values are given per 1-SD increment with the exception of
NYHA.
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clearance is at least a partial explanation
for the correlation of all four peptides
with kidney function. Alternatively or in
addition, the increase in the plasma levels
of the four peptides could also be ex-
plained by increased production due to
endothelial stress.
Although the vasoactive properties
differ, all four peptides act as natriuretic
agents. This natriuretic property is
thought to be beneﬁcial, and the fact that
patients with heart failure do not have in-
creasednatriuresisbutinsteadﬂuidreten-
tion and edema is thought to be due to
(renal) resistance to the effect. Thus, the
upregulation of natriuretic peptides in
heartfailureisthoughttobephysiological
and cardio- and renoprotective. The
higher levels of these peptides in patients
progressing to an event would therefore
represent an increased compensating ef-
fort of the body. Interestingly, in this
study sample all four markers were inde-
pendent predictors of serum creatinine in
themultivariatelinearregressionanalysis.
This interesting ﬁnding underscores the
complex regulation of kidney function
with apparently each of the different
peptide hormones (vasopressin, ad-
renomedullin, endothelin, and atrial na-
triureticpeptide)playingadistinctrolein
the diabetic kidney.
In the study sample presented here,
thestablemarkersofallfourpeptidescor-
related strongly with each other (data not
shown),despitetheirdifferentorigin,and
all of them were higher in patients with a
future event than in those who remained
event free. To our knowledge, this is the
ﬁrst report of the four markers MR-
proADM, CT-proET-1, MR-proANP, and
CT-proAVP in a large sample of patients
with diabetes. The data presented here
describe a close relationship between re-
nal function parameters and the four se-
rum markers and a relationship of MR-
proANP in particular and to a lesser
extent the other three markers and the
occurrence of cardiovascular events over
a time frame of 1 year in a cohort of
diabeticpatients.Thus,thesemarkers(or,
rather, the active peptides for which they
are surrogate markers) could be factors
linking renal function to cardiovascular
events.
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